ClinicalTrials.gg
CompletedNCT03093324Updated Jul 14, 2020Results posted

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

A Phase 3 interventional study of ALKS 8700 and Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 67 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-14.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Biogen.

Enrollment
14th of 59
506 · median 152
Started
2017
with 4 others
Phase 3
25 of 78
none open now
Registered
65th of 78
by date

Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 14th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2017, is one of 25 in phase 3, and was the 65th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen as a file.
02

Study summary

The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability in adult subjects with RRMS after administration of ALKS 8700 or Dimethyl Fumarate (DMF) in Part A, to compare the GI tolerability of ALKS 8700 and DMF in adult subjects with RRMS using IGISIS and GGISIS in Part B, and to Evaluate the safety and tolerability of ALKS 8700 in adult subjects with RRMS in Parts A and B.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis

Keywords

  • RRMS
  • Multiple Sclerosis
  • MS
  • Alkermes
  • ALKS 8700
  • Dimethyl Fumarate
  • DMF
  • Tecfidera
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Capable of understanding and complying with the protocol
  • Has a confirmed diagnosis of RRMS
  • Neurologically stable with no evidence of relapse within 30 days prior to randomization
  • Agrees to use an acceptable method of for the duration of the study and for 30 days after any study drug administration, or is surgically sterile or

Key Exclusion Criteria:

  • Have any finding(s) that would compromise the safety of the subject, affect the subject's ability to adhere to the protocol visit schedule or to fulfill visit requirements, or would make the subject unsuitable for participation in the study
  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
  • History of cardiovascular, pulmonary, GI, dermatologic, psychiatric, neurologic (other than MS), endocrine, renal, and/or other major disease that would preclude participation in a clinical trial
  • History of GI surgery (except appendectomy that occurred more than 6 months prior to screening
  • History of clinically significant recurring or active gastrointestinal symptoms (eg, nausea, diarrhea, dyspepsia, constipation) within 3 months of screening
  • Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month of screening Has a clinically significant medical condition or observed abnormality at screening
  • History of a myocardial infarction, including a silent myocardial infarction or unstable angina
  • History of clinically significant drug or alcohol abuse within the past year prior to screening
  • Clinically significant history of suicidal ideation or suicidal behavior in the last 12 months
  • Subject is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding at any point during the study and for 30 days after any study drug administration
  • Prior use of Dimethyl Fumarate (DMF)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    ALKS 8700

    Oral capsules, administered orally twice daily.

    Drug: ALKS 8700

  • Active comparator
    Dimethyl Fumarate

    Oral capsules, administered orally twice daily.

    Drug: Dimethyl Fumarate

Interventions

  • Administered as specified in the treatment arm.

  • Administered as specified in the treatment arm.

    Also known as: Tecfidera

06

What researchers measure

Primary outcomes

  1. Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B

    IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

Secondary outcomes

  1. Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B

    IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for Part B

  2. Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B

    IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  3. Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B

    IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  4. Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B

    GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  5. Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B

    GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  6. Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B

    GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  7. Worst IGISIS Individual Symptom Intensity Score During the 5-Week Treatment Period in Parts A and B

    IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries. Scores were averaged for 5-week treatment period.

    Time frame: End of treatment (up to Week 6) for both Parts A and B

  8. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: End of study (up to Week 10)

07

Results

Posted Jul 14, 2020

Participant flow

Participants were enrolled at 70 investigative sites in the United States (US), Germany, and Poland from March 15, 2017 to June 27, 2019.

Participant flow — Overall Study
MilestoneALKS 8700Dimethyl Fumarate (DMF)
Started254252
Safety population253251
Completed245233
Not completed919
Withdrew: Adverse event415
Withdrew: Lost to follow-up10
Withdrew: Protocol deviation22
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryNumber of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B

IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B1.5 ± 2.852.5 ± 4.68
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.0003 · Rate ratio: 0.542 · 95% CI 0.390 to 0.754
SecondaryNumber of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B

IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for Part B
Reported as:
Mean · days
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Part B1.3 ± 2.702.2 ± 4.22
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.0007 · Rate ratio: 0.520 · 95% CI 0.356 to 0.760
SecondaryNumber of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B

IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B2.9 ± 4.463.9 ± 5.84
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.009 · Rate ratio: 0.714 · 95% CI 0.554 to 0.921
SecondaryNumber of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B

IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With Any IGISIS Individual Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B0.9 ± 2.251.5 ± 3.85
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.009 · Rate ratio: 0.555 · 95% CI 0.357 to 0.862
SecondaryNumber of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B

GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With a Global GI Symptom and Impact Scale (GGISIS) Symptom Intensity Score ≥1 Relative to Exposure Days in Parts A and B2.1 ± 4.432.8 ± 5.19
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.033 · Rate ratio: 0.696 · 95% CI 0.499 to 0.972
SecondaryNumber of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B

GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With a GGISIS Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B1.1 ± 3.251.5 ± 3.53
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.068 · Rate ratio: 0.662 · 95% CI 0.425 to 1.031
SecondaryNumber of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B

GGISIS is a global scale to assess the overall intensity of GI symptoms (nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea). Participants rated the intensity of GI symptoms via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). GGISIS was completed by the participants using e-diaries.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · days
Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B
daysALKS 8700Dimethyl Fumarate (DMF)
Number of Days With a GGISIS Symptom Intensity Score ≥3 Relative to Exposure Days in Parts A and B0.7 ± 2.260.9 ± 2.57
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · Negative Binomial Regression Model · p = 0.215 · Rate ratio: 0.713 · 95% CI 0.417 to 1.217
SecondaryWorst IGISIS Individual Symptom Intensity Score During the 5-Week Treatment Period in Parts A and B

IGISIS assessed the intensity of five individual GI symptoms: nausea, vomiting, upper abdominal pain, lower abdominal pain, and diarrhea. Participants rated the intensity of each individual symptom via an 11-point numeric rating scale ranging from 0 (did not have) to 10 (extreme). IGISIS was completed by the participants using e-diaries. Scores were averaged for 5-week treatment period.

Time frame:
End of treatment (up to Week 6) for both Parts A and B
Reported as:
Mean · score on a scale
Worst IGISIS Individual Symptom Intensity Score During the 5-Week Treatment Period in Parts A and B
score on a scaleALKS 8700Dimethyl Fumarate (DMF)
Nausea0.9 ± 1.551.2 ± 1.98
Vomiting0.2 ± 0.740.6 ± 1.84
Upper Abdominal Pain0.8 ± 1.581.3 ± 2.06
Lower Abdominal Pain0.8 ± 1.601.0 ± 1.84
Diarrhea1.1 ± 2.091.3 ± 2.19
Statistical analysis
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · ANCOVA · p = 0.043 · Least squares mean difference: -0.3 · 95% CI -0.6 to -0.0
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · ANCOVA · p = <0.001 · Least squares mean difference: -0.4 · 95% CI -0.7 to -0.2
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · ANCOVA · p = 0.001 · Least squares mean difference: -0.5 · 95% CI -0.9 to -0.2
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · ANCOVA · p = 0.403 · Least squares mean difference: -0.1 · 95% CI -0.4 to 0.2
  • ALKS 8700 vs Dimethyl Fumarate (DMF) · ANCOVA · p = 0.261 · Least squares mean difference: -0.2 · 95% CI -0.6 to 0.2
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
End of study (up to Week 10)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsALKS 8700Dimethyl Fumarate (DMF)
Number of Participants With Adverse Events (AEs)198210

Adverse events

Collected over End of study (up to Week 10). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALKS 87000/253 (0%)4/253 (1.6%)175/253 (69.2%)
Dimethyl Fumarate (DMF)0/251 (0%)3/251 (1.2%)191/251 (76.1%)
Most frequent serious events
Most frequent serious events
EventALKS 8700Dimethyl Fumarate (DMF)
Multiple sclerosis relapseNervous system disorders3/2532/251
CholecystitisHepatobiliary disorders0/2531/251
Atrial fibrillationCardiac disorders1/2530/251
Suicide attemptPsychiatric disorders1/2530/251
Most frequent other events
Showing 10 of 22
Most frequent other events
EventALKS 8700Dimethyl Fumarate (DMF)
FlushingVascular disorders83/253102/251
DiarrhoeaGastrointestinal disorders39/25356/251
NauseaGastrointestinal disorders37/25352/251
Abdominal pain upperGastrointestinal disorders17/25339/251
Abdominal painGastrointestinal disorders16/25324/251
VomitingGastrointestinal disorders9/25322/251
ErythemaSkin and subcutaneous tissue disorders20/25321/251
PruritusSkin and subcutaneous tissue disorders18/25318/251
Abdominal pain lowerGastrointestinal disorders15/25317/251
NasopharyngitisInfections and infestations15/25311/251

Baseline characteristics

The Safety population included all enrolled participants who had received at least one dose of study drug during the double-blind Treatment Period.

Age, Continuous
Age, Continuous(years)ALKS 8700Dimethyl Fumarate (DMF)Total
Mean43.7 ± 10.9643.7 ± 9.9043.7 ± 10.44
Sex: Female, Male
Sex: Female, Male(Participants)ALKS 8700Dimethyl Fumarate (DMF)Total
Female177190367
Male7661137
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ALKS 8700Dimethyl Fumarate (DMF)Total
Not Hispanic or Latino248241489
Hispanic or Latino51015
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ALKS 8700Dimethyl Fumarate (DMF)Total
White232227459
Black or African American202040
Other022
Asian011
Multiple races101
Native Hawaiian or Other Pacific Islander011
08

Study locations

67 sites
  • Alkermes Investigational Site
    Cullman, Alabama 35058, United States
  • Alkermes Investigational Site
    Phoenix, Arizona 85004, United States
  • Alkermes Investigational Site
    Tucson, Arizona 85704, United States
  • Alkermes Investigational Site
    Long Beach, California 90806, United States
  • Alkermes Investigational Site
    San Diego, California 92103, United States
  • Alkermes Investigational Site
    Basalt, Colorado 81621, United States
  • Alkermes Investigational Site
    Centennial, Colorado 80112, United States
  • Alkermes Investigational Site
    Denver, Colorado 80209, United States
  • Alkermes Investigational Site
    Middlebury, Connecticut 06762, United States
  • Alkermes Investigational Site
    Stamford, Connecticut 06905, United States
  • Alkermes Investigational Site
    Washington, District of Columbia 20007, United States
  • Alkermes Investigational Site
    Atlantis, Florida 33462, United States
  • Alkermes Investigational Site
    Bradenton, Florida 34209, United States
  • Alkermes Investigational Site
    Maitland, Florida 32751, United States
  • Alkermes Investigational Site
    Naples, Florida 34105, United States
  • Alkermes Investigational Site
    Ormond Beach, Florida 32174, United States
  • Alkermes Investigational Site
    Sarasota, Florida 34233, United States
  • Alkermes Investigational Site
    Tampa, Florida 33634, United States
  • Alkermes Investigational Site
    Vero Beach, Florida 32960, United States
  • Alkermes Investigational Site
    Atlanta, Georgia 30312, United States
  • Alkermes Investigational Site
    Atlanta, Georgia 30327, United States
  • Alkermes Investigational Site
    Atlanta, Georgia 30342, United States
  • Alkermes Investigational Site
    Columbus, Georgia 31904, United States
  • Alkermes Investigational Site
    Evanston, Illinois 60201, United States
  • Alkermes Investigational Site
    Des Moines, Iowa 50314, United States
  • Alkermes Investigational Site
    Lenexa, Kansas 66214, United States
  • Alkermes Investigational Site
    Alexandria, Louisiana 71301, United States
  • Alkermes Investigational Site
    Detroit, Michigan 48202, United States
  • Alkermes Investigational Site
    Golden Valley, Minnesota 55422, United States
  • Alkermes Investigational Site
    Saint Louis, Missouri 63104, United States
  • Alkermes Investigational Site
    Saint Louis, Missouri 63110, United States
  • Alkermes Investigational Site
    Saint Louis, Missouri 63131, United States
  • Alkermes Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Alkermes Investigational Site
    Patchogue, New York 11772, United States
  • Alkermes Investigational Site
    Stony Brook, New York 11794, United States
  • Alkermes Investigational Site
    Syracuse, New York 13210, United States
  • Alkermes Investigational Site
    Charlotte, North Carolina 28203, United States
  • Alkermes Investigational Site
    Greensboro, North Carolina 27405, United States
  • Alkermes Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Alkermes Investigational Site
    Canton, Ohio 44718, United States
  • Alkermes Investigational Site
    Columbus, Ohio 43221, United States
  • Alkermes Investigational Site
    Dayton, Ohio 45417, United States
  • Alkermes Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Alkermes Investigational Site
    Charleston, South Carolina 29406, United States
  • Alkermes Investigational Site
    Greer, South Carolina 29650, United States
  • Alkermes Investigational Site
    Indian Land, South Carolina 29707, United States
  • Alkermes Investigational Site
    Spartanburg, South Carolina 29307, United States
  • Alkermes Investigational Site
    Franklin, Tennessee 37064, United States
  • Alkermes Investigational Site
    Knoxville, Tennessee 37922, United States
  • Alkermes Investigational Site
    Dallas, Texas 75231, United States
  • Alkermes Investigational Site
    Houston, Texas 77030, United States
  • Alkermes Investigational Site
    Houston, Texas 77074, United States
  • Alkermes Investigational Site
    Newport News, Virginia 23601, United States
  • Alkermes Investigational Site
    Richmond, Virginia 23226, United States
  • Alkermes Investigational Site
    Seattle, Washington 98101, United States
  • Alkermes Investigational Site
    Seattle, Washington 98122, United States
  • Alkermes Investigational Site
    Seattle, Washington 98133, United States
  • Alkermes Investigational Site
    Dresden, Germany
  • Alkermes Investigational Site
    Leipzig, Germany
  • Alkermes Investigational Site
    Ulm, Germany
  • Alkermes Investigational Site
    Westerstede, Germany
  • Alkermes Investigational Site
    Gdańsk, 80-803, Poland
  • Alkermes Investigational Site
    Katowice, 40-123, Poland
  • Alkermes Investigational Site
    Kielce, 25-726, Poland
  • Alkermes Investigational Site
    Lodz, 90-324, Poland
  • Alkermes Investigational Site
    Plewiska, 62-064, Poland
  • Alkermes Investigational Site
    Szczecin, 70-111, Poland
09

References and documents

Publications

  • Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, de Seze J, Repovic P, Chen H, Hanna J, Messer J, Miller C, Naismith RT. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021 Mar 19;14:1756286421993999. doi: 10.1177/1756286421993999. eCollection 2021. PubMed 33796143 ↗
  • Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs. 2020 Feb;34(2):185-196. doi: 10.1007/s40263-020-00700-0. PubMed 31953790 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jun 2019, 27 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 27 months is below that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2017
First posted
Mar 28, 2017
StartActual
Mar 15, 2017
Primary completionActual
Jun 27, 2019
CompletionActual
Jun 27, 2019
Results first posted
Jul 14, 2020
Last update
Jul 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03093324
Lead sponsor
Biogen
Collaborators
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
Mar 15, 2017
Primary completion
Jun 27, 2019
Completion
Jun 27, 2019
Results posted
Jul 14, 2020
Last update
Jul 14, 2020

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diroximel fumarate

Start the discussion